Antimicrobial hydrogel formulation

Information

  • Patent Grant
  • 10758426
  • Patent Number
    10,758,426
  • Date Filed
    Tuesday, November 21, 2017
    7 years ago
  • Date Issued
    Tuesday, September 1, 2020
    4 years ago
Abstract
A hydrogel formulation is provided for use with a film. The hydrogel formulation includes a medical-grade hydrogel and an antimicrobial substance. This hydrogel formulation may be coated onto one or more surfaces of a medical-grade transparent film suitable for a wound dressing. The antimicrobial material may be a silane quaternary ammonium salt. The silane quaternary ammonium salt may comprise 3-(trimethoxysilyl) propyldimethyloctadecyl ammonium chloride. The 3-(trimethoxysilyl) propyldimethyloctadecyl ammonium chloride may constitute about 72% by weight of the silane quaternary ammonium salt. The medical-grade hydrogel may comprise a colloidal gel in which the particles are dispersed in water. Further, the hydrogel formulation may include about 0.01% to about 60% by weight of the antimicrobial substance. The transparent film may further include a release liner applied over the coated side(s) of the transparent film. The transparent film may comprise polyurethane.
Description
BACKGROUND OF THE INVENTION

The embodiments described herein generally relate to a hydrogel formulation and to medical supplies including hydrogel formulations such as film dressings, and more particularly IV securement dressings, and wound dressings.


SUMMARY OF THE INVENTION

According to an embodiment of the present invention, a transparent film dressing is provided that comprises a transparent film and a hydrogel adhesive formulation coated on one or more sides of the transparent film. The transparent film comprises polyurethane. The hydrogel formulation comprises a medical-grade hydrogel and an antimicrobial substance, wherein the medical-grade hydrogel comprises a colloidal gel in which the particles are dispersed in water. The antimicrobial material is a silane quaternary ammonium salt comprising 3-(trimethoxysilyl) propyldimethyloctadecyl ammonium chloride. The 3-(trimethoxysilyl) propyldimethyloctadecyl ammonium chloride may constitute about 72% by weight of the silane quaternary ammonium salt. The hydrogel formulation may include about 0.01% to about 60% by weight of the antimicrobial substance. The transparent film dressing may further comprise a release liner applied over one or more coated sides of the transparent film.


According to another embodiment of the present invention, a hydrogel formulation is provided for use on a film dressing, the hydrogel formulation comprising a medical-grade hydrogel and an antimicrobial substance. The film dressing may be transparent or opaque.


According to another embodiment of the present invention, a transparent film dressing is provided that comprises a transparent film having a hydrogel adhesive formulation coated on one or more sides, where the hydrogel formulation comprises a medical-grade hydrogel and an antimicrobial substance. The transparent film dressing may further include a release liner applied over the coated side(s) of the transparent film. The transparent film may comprise polyurethane.


In the latter two embodiments, the antimicrobial material may be a silane quaternary ammonium salt. The silane quaternary ammonium salt may comprise 3-(trimethoxysilyl) propyldimethyloctadecyl ammonium chloride. The 3-(trimethoxysilyl) propyldimethyloctadecyl ammonium chloride may constitute about 72% by weight of the silane quaternary ammonium salt.


Also in these two embodiments, the medical-grade hydrogel may comprise a colloidal gel in which the particles are dispersed in water. Further, the hydrogel formulation may include about 0.01% to about 60% by weight of the antimicrobial substance.


These and other features, advantages, and objects of the present invention will be further understood and appreciated by those skilled in the art by reference to the following specification, claims, and drawings.





BRIEF DESCRIPTION OF THE DRAWINGS

In the drawings:



FIG. 1 is a front elevational view of an IV securement dressing according to a first embodiment;



FIG. 2 is an exploded perspective view of the IV securement dressing shown in FIG. 1;



FIG. 3 is a front elevational view of an IV securement dressing according to a second embodiment; and



FIG. 4 is a perspective view of the IV securement dressing shown in FIG. 3.





DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Reference will now be made in detail to the present preferred embodiments of the invention.


A novel hydrogel formulation for film dressings is disclosed herein that not only provides the requisite properties for a hydrogel, but also eliminates bacteria on contact. In general, the hydrogel formulation comprises a hydrogel and an antimicrobial substance, such as a silane quaternary ammonium salt. The hydrogel may be a medical-grade colloidal gel in which the particles are dispersed in water. Preferred commercially available silane quaternary ammonium salts include: MicrobeCare™ XLP, which is available from MicrobeCare, LLC of Allendale, Mich.; “PROMOFRESH X 105” from Piedmont Chemical Industries I, LLC of High Point, N.C.; and AEM 5772 Antimicrobial, which is available from Aegis Environments of Midland, Mich. These particular antimicrobial substances include an active ingredient of about 72% by weight 3-(trimethoxysilyl) propyldimethyloctadecyl ammonium chloride and about 28% by weight inert ingredients. The antimicrobial substance could also be AEGIS Microbe Shield™ (from Aegis Environments, Midland, Mich.), which is a copolymer of chloropropyltrihydroxysilane and octadecylaminodimethyltrihydroxysilylpropyl ammonium chloride.


Silane quaternary ammonium salts are particularly well suited for the antimicrobial material as they are long lasting and capable of emitting ions that aid in the destruction of a microbe. In addition, they are organofunctional silanes that include a monomer including a silane, a positively charged nitrogen molecule, and a long molecular chain. The silane bases of these monomers can covalently and permanently bond to each other and any surface. In addition, silane quaternary ammonium salts are preferable as they are substantially free from arsenic, silver, tin, heavy metals and polychlorinated phenols. Also, they are safe to apply to the skin or to a wound of a patient.


Microbes may include bacteria, mold, mildew, algae, etc. The cell membranes of the microbes are attracted to, and then are punctured by, the long molecular chains of the monomers. As the microbes are drawn closer because of the positive-negative ion exchanges, the monomers penetrate further into the cell membranes. Once the cell membranes are penetrated deeply, they are physically ruptured by a sword-like action and then electrocuted by positively charged nitrogen molecules of the monomers, thus destroying the microbes. Thus, the microbes are eliminated without “using up” any of the antimicrobial active ingredients, which remain in the adhesive formulation ready to continue protecting the patient against further microbial contamination.


The antimicrobial substance may be mixed into the hydrogel in various amounts of anywhere from about 0.01% to about 60% by weight to achieve the desired degree of antimicrobial activity while not compromising the desirable properties of the hydrogel in the resulting mixture.


As shown in the drawings, the hydrogel formulation 2 is coated on one side or both sides of a medical-grade film 1 (i.e., plastic carrier), which may be a transparent film of the type commonly used for wound dressings or securing an intravenous (IV) needle or catheter. One suitable transparent film is a 1-mil polyurethane film available from DermaMed Coatings Company, LLC of Tallmadge, Ohio. The film 1 is preferably oxygen permeable and may have an optional slit 4 for an IV needle or catheter. The coating method may be a knife-over-roll method. According to a first embodiment shown in FIGS. 1 and 2, a release liner 5 may be applied to the coated side(s) of the transparent film 1. A woven fabric piece 3 may be provided at one end of the film 1. In the second embodiment shown in FIGS. 3 and 4, a release liner 5 is not used.


The hydrogel-coated transparent film may be used as a wound dressing or for any other medical use such as securing an IV needle to a patient or securing a catheter.


The film may also be opaque and may be of the type that is commonly used for bandages or medical tape.


Modifications of the invention will occur to those skilled in the art and to those who make or use the invention. Therefore, it is understood that the embodiments described above are merely for illustrative purposes and not intended to limit the scope of the invention, which will be defined by claims as interpreted according to the principles of patent law, including the doctrine of equivalents.

Claims
  • 1. A hydrogel adhesive formulation for use as a coating on a film dressing comprising: a medical-grade hydrogel comprising a colloidal gel in which particles are dispersed in water; andan antimicrobial substance;wherein, the antimicrobial substance is a silane quaternary ammonium salt comprising 3-(trimethoxysilyl) propyldimethyloctadecyl ammonium chloride.
  • 2. The hydrogel adhesive formulation of claim 1, wherein said hydrogel adhesive formulation includes about 0.01% to about 60% by weight of said antimicrobial substance.
CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation of and claims priority to U.S. patent application Ser. No. 14/049,319, entitled “ANTIMICROBIAL HYDROGEL FORMULATION,” filed on Oct. 9, 2013, which claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No. 61/711,421, entitled “ANTIMICROBIAL HYDROGEL FORMULATION” filed on Oct. 9, 2012, the entire disclosures of which are incorporated herein by reference.

US Referenced Citations (55)
Number Name Date Kind
4372303 Grossmann et al. Feb 1983 A
4865844 Blank et al. Sep 1989 A
4921691 Stockel May 1990 A
5079004 Blank et al. Jan 1992 A
5183664 Ansell Feb 1993 A
5270358 Asmus Dec 1993 A
5428078 Cohen et al. Jun 1995 A
5762623 Murphy et al. Jun 1998 A
5954869 Elfersy et al. Sep 1999 A
5959014 Liebeskind et al. Sep 1999 A
6224579 Modak et al. May 2001 B1
6495229 Carte et al. Dec 2002 B1
6821943 Avery et al. Nov 2004 B2
6994890 Ohlhausen et al. Feb 2006 B2
7045673 Batich et al. May 2006 B1
7704313 Ohlhausen et al. Apr 2010 B2
7709694 Batich et al. May 2010 B2
7754004 Ohlhausen et al. Jul 2010 B2
7790217 Toreki et al. Sep 2010 B2
8025120 Eddy Sep 2011 B2
8257780 Ohlhausen et al. Sep 2012 B2
8440217 El-Naggar et al. May 2013 B1
8491922 Eddy Jul 2013 B2
8639527 Rensvold et al. Jan 2014 B2
8679526 Van Den Plas et al. Mar 2014 B2
9028846 Eddy May 2015 B2
9433708 Eddy Sep 2016 B2
9675735 Eddy Jun 2017 B2
9717249 Eddy Aug 2017 B2
9877875 Eddy Jan 2018 B2
20020111282 Charaf et al. Aug 2002 A1
20070021383 Loder Jan 2007 A1
20070042198 Schonemyr et al. Feb 2007 A1
20070218096 Wooley Sep 2007 A1
20080260804 Morris et al. Oct 2008 A1
20090215917 Trotter et al. Aug 2009 A1
20090223411 Higgins et al. Sep 2009 A1
20090252647 Orofino Oct 2009 A1
20090312684 Leonard et al. Dec 2009 A1
20100028462 Bolkan et al. Feb 2010 A1
20100167978 Iyer et al. Jul 2010 A1
20100331710 Eddy Dec 2010 A1
20110200655 Black et al. Aug 2011 A1
20110233810 Neigel et al. Sep 2011 A1
20120173274 Rensvold et al. Jul 2012 A1
20130101677 Callahan et al. Apr 2013 A1
20130231599 Eddy Sep 2013 A1
20130345170 Eddy Dec 2013 A1
20140100504 Eddy Apr 2014 A1
20140271794 Eddy Sep 2014 A1
20160143275 Lan et al. May 2016 A1
20160143276 Lan et al. May 2016 A1
20160262382 Lan et al. Sep 2016 A1
20160262383 Lan et al. Sep 2016 A1
20170280716 Lan et al. Oct 2017 A1
Foreign Referenced Citations (8)
Number Date Country
0054587 Sep 2000 WO
0072850 Dec 2000 WO
2005042657 May 2005 WO
2007061625 May 2007 WO
2007076413 Jul 2007 WO
2008076839 Jun 2008 WO
2008097599 Aug 2008 WO
2013102021 Jul 2013 WO
Non-Patent Literature Citations (7)
Entry
Rutala et al., “Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008,” Centers for Disease Control (CDC), Department of Health & Human Services, Feb. 15, 2017 (161 pages).
U.S. Food & Drug Administration (FDA), “Reprocessing Medical Devices in Health Care Settings: Validation Methods and Labeling Guidance for Industry and Food and Drug Administration Staff,” Mar. 17, 2015 (44 pages).
European Commission, “Aerosol Dispensers Directive Evaluation—Background document”, Sep. 23, 2016, Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs, Belgium (1 page).
Monticello, Robert A., “The Use of Reactive Silane Chemistries to Provide Durable, Non-Leaching Antimicrobial Surfaces”, AEGIS Environments, Midland, Michigan USA, Jan. 1, 2010 (77 pages).
AEGIS Environments, Material Safety Data Sheet AEGIS Microbe Shield(TM) Program—AEGIS(TM) Antimicrobial (Typical Application Strength), Midland, Michigan USA, May 12, 2004 (5 pages).
Anonymous, 2009, SiSiB PC9911 Antimicrobial, Power Chemical Corp, [online]; downloaded from URL<http://www.powerchemcorp.com/library/public/SiSiB_PC9911.pdf> on Oct. 8, 2013; 2 pages.
Murray et al, “Microbial Inhibition on Hospital Garments Treated with Dow Corning 5700 Antimicrobial Agent,” Journal of Clinical Microbiology, vol. 26, No. 9, Sep. 1988, pp. 1884-1886.
Related Publications (1)
Number Date Country
20180092780 A1 Apr 2018 US
Provisional Applications (1)
Number Date Country
61711421 Oct 2012 US
Continuations (1)
Number Date Country
Parent 14049319 Oct 2013 US
Child 15819381 US